Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, ##STR00001##
and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Herbicides, systems, and methods for inhibiting germination of a root parasitic plant are provided. In particular, the herbicide includes an active compound represented by Formula I. In this regard, the active compound is selected to bind to an active site of strigolactone receptors in seeds of the root parasitic plant.

Herbicides, systems, and methods for inhibiting germination of a root parasitic plant are provided. In particular, the herbicide includes an active compound represented by Formula I. In this regard, the active compound is selected to bind to an active site of strigolactone receptors in seeds of the root parasitic plant.

Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I,

##STR00001##

and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Compounds are provided having the structure of Formula (I):

##STR00001##

or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein A, X.sup.1, X.sup.2, Q, R.sup.1, R.sup.2 and n are as defined herein. Such compounds function as thyromimetics and have utility for treating diseases such as neurodegenerative disorders and fibrotic diseases. Pharmaceutical compositions containing such compounds are also provided, as are methods of their use and preparation.

Compounds are provided having the structure of Formula (I):

##STR00001##

or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein A, X.sup.1, X.sup.2, Q, R.sup.1, R.sup.2 and n are as defined herein. Such compounds function as thyromimetics and have utility for treating diseases such as neurodegenerative disorders and fibrotic diseases. Pharmaceutical compositions containing such compounds are also provided, as are methods of their use and preparation.

Disclosed is a preparation method of phenoxycarboxylic acid herbicides. The preparation method comprises the following steps. S1: mixing an anhydrous phenol and a basic substance with a chloro-substituted carboxylic acid ester and performing a one-pot condensation reaction in an anhydrous system to obtain a phenoxycarboxylic acid ester. The chloro-substituted carboxylic acid ester is represented by the formula ClR.sub.1COOR, in which R.sub.1 is a C1-3 alkanediyl or alkylidene group, R is a C1-10 alkyl group or a C3-10 cycloalkyl group; S2: the phenoxycarboxylic acid ester undergoes selective chlorination with a chlorinating agent in the presence of a first catalyst and a second catalyst to obtain a chloro-substituted phenoxycarboxylic acid ester; and S3: the chloro-substituted phenoxycarboxylic acid ester undergoes an acid hydrolysis reaction to obtain a phenoxycarboxylic acid herbicide represented by formula I, in which R.sub.3 is H, Cl or CH.sub.3.

##STR00001##

Disclosed is a preparation method of phenoxycarboxylic acid herbicides. The preparation method comprises the following steps. S1: mixing an anhydrous phenol and a basic substance with a chloro-substituted carboxylic acid ester and performing a one-pot condensation reaction in an anhydrous system to obtain a phenoxycarboxylic acid ester. The chloro-substituted carboxylic acid ester is represented by the formula ClR.sub.1COOR, in which R.sub.1 is a C1-3 alkanediyl or alkylidene group, R is a C1-10 alkyl group or a C3-10 cycloalkyl group; S2: the phenoxycarboxylic acid ester undergoes selective chlorination with a chlorinating agent in the presence of a first catalyst and a second catalyst to obtain a chloro-substituted phenoxycarboxylic acid ester; and S3: the chloro-substituted phenoxycarboxylic acid ester undergoes an acid hydrolysis reaction to obtain a phenoxycarboxylic acid herbicide represented by formula I, in which R.sub.3 is H, Cl or CH.sub.3.

##STR00001##

A compound of the formula (I) wherein R represents a straight or branched, primary or secondary acyclic hydrocarbyl C3-C15 group, which can be saturated or unsaturated, or a straight or branched, primary or secondary acyclic hydrocarbyl C3-C15 group, which can be saturated or unsaturated and wherein one or more of hydrogen atoms is replaced with fluorine atom; X represents hydrogen atom or halogen atom, and * denotes chiral center, and salts thereof. The compound is useful for the treatment of diseases mediated by GPR40, in particular type II diabetes. (I)

##STR00001##

A compound of the formula (I) wherein R represents a straight or branched, primary or secondary acyclic hydrocarbyl C3-C15 group, which can be saturated or unsaturated, or a straight or branched, primary or secondary acyclic hydrocarbyl C3-C15 group, which can be saturated or unsaturated and wherein one or more of hydrogen atoms is replaced with fluorine atom; X represents hydrogen atom or halogen atom, and * denotes chiral center, and salts thereof. The compound is useful for the treatment of diseases mediated by GPR40, in particular type II diabetes. (I)

##STR00001##